Biomarkers of mineralocorticoid receptor activation
US10041122B2 · kind B2 · utility
0Cited by
3References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2016 |
| Grant date | Aug 7, 2018 |
| Priority date | — |
| Expiry date | Jun 21, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.